pharmaphorum

OCTOBER 10, 2022

The results of the STELLAR trial showed that the activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein achieved a significant increase in exercise capacity measured using the six-minute walking test in PAH patients when added to stable background therapy, hitting its primary objectives.

Sales 52

Sales FDA Pharma Competition 52

PM360

APRIL 7, 2023

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

pharmaphorum

AUGUST 8, 2022

billion in 2028 – a leap forward from the $195 million it made last year and $127 million in the first half of 2022. billion acquisition of Arena Pharma , bringing on board etrasimod in late-stage testing for ulcerative colitis, and made an $11.6 $PFE $GBT [link] pic.twitter.com/52AMCbvFHF.

Marketing 102

Marketing Sales Pharma FDA 102

Pharmaceutical Technology

SEPTEMBER 2, 2022

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration 59

Food and Drug Administration FDA Sales Physicians 59

Pharmaceutical Technology

JANUARY 19, 2023

While allogeneic hematopoietic stem cell transplants (HSCT) provide long-term benefit to a subset of AML patients, other cell therapy modalities such as natural killer (NK) cells or chimeric antigen receptor (CAR)-T cells have failed to show conclusive benefit in late-stage clinical trials.

Marketing 52

Marketing FDA Sales Management 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

pharmaphorum

JANUARY 5, 2023

A new operating model for pharma shifted priorities and forced companies to rethink their organisational strategies. Everything from transitioning to virtual meetings with healthcare providers, to navigating the logistics of supply chain disruptions, has permanently altered pharma operations – many would say for the better.

Pharmaceutical 64

Pharmaceutical Recruitment Training Education 64

Clarivate

APRIL 18, 2024

While the key players’ strategies differ, all are focused on bending the cost curve while increasing patient touchpoints and engagement. More recent developments provide a look into Amazon’s interest in treating patients with chronic conditions, including a pharmacy consultation pilot for high-risk seniors with complex medical needs.

Retail 52

Retail Healthcare Healthcare Physicians 52

Contrarian Sales Techniques

FEBRUARY 10, 2023

They are designed to be safe and comfortable for patients, and typically have minimal side effects. According to various market research reports, the global non-invasive medical devices market was valued at approximately USD 45 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of over 6% from 2021 to 2028.

Healthcare 52

Healthcare Healthcare Manufacturing Medical 52

European Pharmaceutical Review

MARCH 25, 2024

The facility is planned to be operational by 2028, Astellas said. Today marks a significant achievement for our company and reflects our continued commitment to expansion and innovation in the region,” declared Hideki Shima, Chief Manufacturing Officer, Astellas Pharma. The new facility will be built with “sustainability at its core”.

Manufacturing 79

Manufacturing Pharmaceutical manufacturing Engineering Government 79

European Pharmaceutical Review

OCTOBER 12, 2023

With the goal of supplying cell therapies, vaccines and other essential medicines such as antibody drugs to patients, the facilities aim to address major supply challenges and navigate the intricacies of producing fragile biological products. Astellas – sustainable innovation September also saw Astellas Pharma Inc. Kerry, Ireland.

Pharmaceutical manufacturing 84

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharma 84

pharmaphorum

OCTOBER 10, 2022

Detecting patients with cancer as early as possible gives clinicians the best chance to formulate a successful treatment response. Any delay in diagnosis or treatment can severely impact the options available to patients and healthcare professionals. Time is a precious resource in oncology.

Patients 89

Patients Pharma Media Training 89

Pharmaceutical Technology

FEBRUARY 13, 2023

According to the GlobalData Pharma Intelligence Center, there are currently 71 PROTACs in development in the oncology pipeline by non-academic developers, mostly clustering in the preclinical and discovery phases, with only 14 agents in clinical stages. Among 44 patients with measurable disease, two had confirmed partial responses.

Competition 59

Competition Safety Patients Pharmaceutical 59

pharmaphorum

AUGUST 2, 2022

As the technology has developed, the interest from larger pharma companies has continued to grow, resulting in a number of acquisitions and partnerships taking place to gain access to the technology. Looking to the future. It is for this reason that Merck is prepared to pay substantial sums to add ADC prospects and expertise to its business.

Marketing 91

Marketing Prospecting Sales Pharma 91

pharmaphorum

OCTOBER 18, 2022

per share – values Akouos at $487 million and includes another $3 per share in a contingent value right (CVR) ties to the enrolment of patients into the gene therapy company’s clinical trials. per month if conditions are not met, until the end of 2028 when they will all expire. The buyout – for $12.50

Medicine 52

Medicine FDA Patients Pharma 52

World of DTC Marketing

DECEMBER 15, 2021

Together with the growth in wearables—projected to be worth nearly $120 billion by 2028—we are seeing growing democratization of knowledge of one’s own body, with tech enabling consumers to take a more active and regular role in their healthcare. What’s so ironic is that pharma could develop an app to compliment some of their drugs.

Doctors 208

Doctors Medical Patients Marketing 208

Pharmaceutical Technology

DECEMBER 22, 2022

The EUnetHTA aims to achieve a high level of health protection for patients and establish a framework to support member state cooperation on the clinical assessment of health technologies. The new joint procedure will launch in Q1 2025 for oncology medicines and other advanced therapy medicinal products and extend to orphan drugs in 2028.

Medicine 52

Medicine Pharma Marketing Distribution 52

World of DTC Marketing

JULY 28, 2022

Nationwide, prescription drug spending last year is estimated to be $328 billion among all payers, including private insurance, Medicare Part D, and patients’ out-of-pocket expenses. Still, the pharma industry is fighting hard to keep it off the table. Pharma is a very profitable industry. The secretary of the U.S.

Pharma 256

Pharma Prescription Manufacturing Insurance 256